Original Research Paper



Nephrology

OUTCOMES OF RENAL TRANSPLANTATION WITH SIBLING AND SPOUSAL DONORS; A COMPARATIVE STUDY

Dr. M. V. K. Hareesh*

D.M. (Nephrology) Senior Resident, S G P G I, LUCKNOW *Corresponding Author

Dr. R. K. Sharma

Professor of Nephrology, S G P G I, LUCKNOW

ABSTRACT

BACKGROUND: Kidney transplantation is the best treatment for End stage renal disease. In the recent years due to increase in number of patients requiring transplantation, there is a shortage of donor organs. Spousal transplantation is emerging as an important way of increasing the donor pool. We present a comparison between Spousal donors (SPD) and sibling donors (SID).

METHODS: 202 renal transplant recipients, 101 with sibling donors and 101 with spousal donors matched for age and sex of donor and year of transplantation were compared. Outcomes like graft and patient survival, early and late graft rejections, infections, post-transplant diabetes mellitus, recurrence of diseases were compared.

RESULTS: During follow up there is no significant difference between graft and patient survival between the two groups. Graft rejections were more common among the SPD group but were not statistically significant. Recurrences of diseases were more often observed in SID group. The incidence of infections were similar between two groups.

CONCLUSION: The outcomes of spousal donor (SPD) and sibling donor(SID) transplant recipients were equivalent. An emotionally motivated spousal donor is the solution for the shortage of donor organs as sibling donations are declining in recent years.

KEYWORDS: Kidneytransplantation, sibling donors, spousal donors

INTRODUCTION.

Ever since the transplantation of human organs started it has undergone numerous changes. First started the transplantation between identical twins(1).HLA matching has played a key role in determining the donor pool.HLA-DR mismatches are associated with a risk of early graft rejection and graft loss whereas HLA-A,HLA-B antigen mismatches are associated with late graft rejection and loss(2)(.It has been experienced that recipients of living unrelated donors have better outcomes when compared to cadaveric donors. This led to illegal organ trafficking in many parts of the world including India(3). After the enforcement of Transplantation of Human organs Act 1994(4),the scenario has changed. Near relatives are the spouses, siblings, parents and children who are 18 yrs of age or older. Special Authorisation committee is required for all other donors. Spouse as donor embodies psychosocial considerations and careful decision making on part of the caregivers. In our centre there has been steady increase in the number of spousal donors over the past 10 years. The number of sibling donors has decreased but the number of parental donors have increased probably due to the decrease in joint family system. A few number of studies were done comparing the donor category and transplant outcomes like between spousal and other related donors, maternal and paternal donors.(5)

MATERIAL AND METHODS

A retrospective cohort study of 202 Living related kidney transplant recipients with sibling or spouse as donor from January 2006 to December2015 of kidney transplants done at SGPGI, LUCKNOW, were included in the study. Sample included patients in either group who can be matched with a recipient whose donor sex, age were matched and transplanted in the same year. Among them 101 patients had spousal donors and 101 patients had sibling donors. The spousal donor and sibling donor transplant recipients groups were matched for the age and sex of the donor. All were ABO compatible transplantations. The induction and immunosuppression received were comparable between two groups. These patients were followed up till November 2016.

Patients were given immunosuppression with either cyclosporine or tacrolimus combined with MycophenolateMofetil and prednisolone. From 2012 all patients received Tacrolimusimmunosuppression. The age and sex of the donors were matched while including patients into the study. Choice of induction was based on immunological risk. Second transplants, patients with prior cross match positivities, patients with DSA positivity were given Antithymocyteglobulin. Standard protocols were followed for surgery and antibiotic Cotrimoxazole and antifungal prophylaxis with clotrimazole lozenges or mouth paint were given. Empirical Methyl prednisolone was given during postoperative period based on Clinician's discretion for suspected rejection as most early rejections

are mild and responded to methyl prednisolone. Some patients were switched to Everolimus due to biopsy proven CNI toxicity.

SPSS statistics software version 20 was used for statistical calculations. Kaplan Meier curves were used to compare survival Death censored graft survival was used for graft survival. Chi-square test was used to compare significance in categorical variables and Independent samples T test was used for non-categorical variables.

BASELINE CHARACTERISTICS

	SIBLING	SPOUSAL	P
	DONOR	DONOR	VALUE
	GROUP	GROUP	
	(SID)	(SPD)	
	(n=101)	(n=101)	
SEX			0.582
MALE	81(80.2%)	85(84.2%)	
FEMALE	20(19.8%)	16(15.8%)	
AGE-MEAN(YRS)	42.86+/-	44.97+/-	>0.05
	10.46	8.14	(1.00)
BASIC KIDNEY DISEASE			0.146
CGN	63(62.4%)	49(48.5%)	
CIN	21(20.8%)	36(35.6%)	
DKD	13(12.9%)	15(14.9%)	
RIGHT SOLITARY	1(1%)		
B/L SCARRED	1(1%)		
HYPERTENSIVE	1(1%)		
NEPHROSCLEROSIS			
ADPKD		1(1%)	
DGGS	1(1%)		
COMORBIDITIES			
D.M.	14(13.9%)	15(14.9%)	>0.05
			(1.00)
CAD	2(2%)	5(5%)	0.248
H/O BLOOD	31(30.7%)	24(23.8%)	0.343
TRANSFUSIONS			
SECOND TRANSPLANT	4(4%)	5(5%)	0.733
H/O PREGNANCIES	1(1%)	7(6.9%)	0.029
DIALYSIS DURATION	9.80+/-7.62	9.54+/-7.82	0.895
(MONTHS)			
BLOOD GROUP			0.576
A POSITIVE	19(18.8%)	22(21.8%)	
A NEGATIVE	1(1%)	1(1%)	
B POSITIVE	32(31.7%)	40(39.6%)	
AB POSITIVE	11(10.9%)	14(13.9%)	
AB NEGATIVE			

INDIAN JOURNAL OF APPLIED RESEARCH

O POSITIVE	32(31.7%)	21(20.8%)	
O NEGATIVE	4(4%)	2(2%)	
Donor relation			< 0.001
SISTER	82(40.6%)		
BROTHER	19(8.8%)		
HUSBAND		19(8.8%)	
WIFE		82(40.6%)	
MEAN AGE(YRS)	40.72+/-	41.41+/-	0.481
	10.21	9.37	
BLOOD GROUP DONOR			0.485
A POSITIVE	18(17.8%)	10(9.9%)	
A NEGATIVE			
B POSITIVE	30(29.7%)	28(27.7%)	
B NEGATIVE	2(2%)	1(1%)	
AB POSITIVE	2(2%)	2(2%)	
O POSITIVE	48(47.5%)	57(56.4%)	
O NEGATIVE	1(1%)	3(3%)	



HLA DR MATCH	SIBLING DONOR	SPOUSAL	< 0.001
	(SID)	DONOR (SPD)	
0	8(8.2%)	53(54.1%)	
1	61(62.2%)	43(43.9%)	
2	29(29.6%)	2(2%)	
HLA MATCH			< 0.001
0	6(6.3%)	23(24.7%)	
1	5(5.3%)	33(35.5%)	
2	9(9.5%)	19(20.4%)	
3	42(43.2%)	15(16.1%)	
4	16(16.8%)	1(1.1%)	
5	11(11.6%)	2(2.2%)	
6	7(7.4%)	0	



HLA MATCH - SPOUSAL

RESULTS

A total of 202 kidney transplant recipients were compared. Only the patients with sibling donors or spousal donors were chosen for analysis and matched for the age and sex of the donor and length of the follow up period. Among the recipients of sibling donors, 80.2% (n=81) were males and 19.8% (n=20) were females where as in spousal donor group 84.2% (n=85) were males and 15.8% (n=16) were females. There was no significant difference in the male and female distribution between the two groups (p=0.582). The recipients of the SPD group were slightly older than the recipients of the SID group (mean age+/-Standard deviation 44.97+/-8.14 yrs Vs.42.86+/-10.46 yrs, p>0.05).

There was difference in the basic disease of the recipient in the two groups. Chronic glomerulonephritis was the commonest but the proportion was more in the SID group (62.4%) than the SPD group(48.5%), whereas the percentage of Chronic interstitial nephritis was more in SPD group than the SID group(35.6% vs 20.8%). Diabetic kidney disease was nearly equal in both (SID 12.9%(n=13) vs SPD 14.9%(n=15)).


More recipients in the SID group received blood transfusions compared to the SPD group (30.7% vs 20.8%)(p=0.343). More recipients in the SPD group had previous pregnancies compared to SID group (6.9%, n=7 vs 1%, n=1)p=0.029. DSA positivity was observed in

4% of recipients in SPD group compared to none in SID group. Flow cytometry cross match positivity was seen in 3% of patients in SID group and 5% of patients in SPD group.

IMMUNOLOGICAL SIBLING SPOUSAL P					
		P			
DONOR	DONOR	Value			
GROUP(SID)	GROUP(SPD)				
3(3%)	1(1%)	0.312			
2(2%)	2(2%)	>0.05			
83(82.2%)	81(80.2%)	0.247			
	3(3%)				
	1(1%)				
		0.518			
85	84				
13	12				
3(3%)	2(2%)				
	, ,				
0	1(1%)				
0	2(2%)				
	SIBLING DONOR GROUP(SID) 3(3%) 2(2%) 83(82.2%) 85 13 3(3%)	SIBLING SPOUSAL			

DONOR	SIBLING	SPOUSAL	
CHARACTERISTICS	DONOR	DONOR	
	GROUP	GROUP	
	(SID)	(SPD)	
DONOR COMORBIDITIES			P VALUE-
			0.439
HYPERTENSION	3(3%)	6(6%)	
HYPOTHYROIDISM	1(1%)	2(2%)	
RENAL STONE	1(1%)	2(2%)	
PREVIOUS TB	2(2%)	2(2%)	
BRONCHITIS	1(1%)		
RENAL CYST		1(1%)	
NO COMORBIDITY	91(91%)	84(84%)	
GFR			
TOTAL MEAN GFR	85.31+/-	84.09+/-	0.773
	16.45	15.59	
GFR OF TRANSPLANTED	42.29+/-	41.86+/-	0.771
KIDNEY	8.67	7.91	
PREVIOUS SURGERIES	24(23.9%)	31(31%)	0.160
DONOR			
SURGERY			
CHARACTERISTICS			
MULTIPLE VESSELS	16(15.8%)	17(16.8%)	>0.05
DIFFICULT SURGERY		2(2%)	0.155
POST OPERATIVE ACUTE	7(6.9%)	3(3%)	0.206
TUBULAR NECROSIS			
IMMUNOSUPPRESSION			0.546
TACROLIMUS	65(64.4%)		
CYCLOSPORINE	35(34.7%)	30(29.7%)	
CHANGE TO EVEROLIMUS	4(4%)	2(2%)	0.407
INDUCTION			0.917
ATG	8(7.9%)	10(9.9%)	
BASILIXIMAB	41(40.6%)	39(38.6%)	
DACLIZUMAB	2(2%)	3(3%)	
NO INDUCTION	49(48.5%)	47(46.5%)	
	· · · · · · · · · · · · · · · · · · ·		

DONOR COMORBIDITIES





In the SID group, 82 were sisters and 19 were brothers where as in SPD group, 82 were wives and 19 were husbands. The mean age of donors in both the groups was 40.72 and 41.41 yrs respectively. The comorbidities and mean GFR between the two groups was similar (85.31+/-16.45ml/mt Vs 84.09+/-15.59ml/mt). The total degree of HLA match and HLA DR match was significantly more in SID group than the SPD group (p<0.01). The percentage of donors with previous surgeries were comparable between these two groups. (23.9% vs 31%,p=0.16). Percentage of grafts with multiple vessels was also comparable (15.8% vs 16.8%).

There was no significant difference in the proportion of recipients who received induction in the SID group compared with SPD group(SID,n=49,51.5%;SPD,n=47,53.5%;p=0.917). The proportion of patients who received Antithymocyte globulin (SID(7.9%) vs SPD(9.9%)) and basiliximab(SID 40.6% vs SPD 38.6%) as induction was also similar. There was no difference in the proportion of patients with Tacrolimus immunosuppression (SID,64.4% Vs SPD 69.3%,p=0.546) in between two groups. Four patients were changed from CNI to Everolimus immunosuppression in SID group when compared to two in SPD group.

OUTCOMES STEROID PULSE 15(14.9%) 17(16.8%) 0.230 HOSPITAL STAY 1(1%) 5(5%) RESPONSE TO STEROID 11(10.9%) 13(12.9%) PULSE DURATION HOSPITAL 23.44+/-11.47 24.5+/-13.10 0.615 EARLY BIOPSY PROVEN REJECTIONS 11(10.9%) 16(15.8%) 0.409 REJECTIONS 6(5.9%) 9(8.9%) 0.593 TOTAL ACUTE REJECTIONS 17(16.8%) 24(23.7%) 0.502 REJECTION TYPE 0.486 ACR 7(6.9%) 12(11.9%) ACR ACR 7(6.9%) 12(11.9%) ACR ACR 4(4%) ACR <	compared to two in SPD group.			
HOSPITAL STAY	OUTCOMES			
ATG SECONDARY 1(1%) 5(5%) RESPONSE TO STEROID PULSE 11(10.9%) 13(12.9%) DURATION HOSPITAL 23.44+/-11.47 24.5+/-13.10 0.615 EARLY BIOPSY PROVEN REJECTIONS 11(10.9%) 16(15.8%) 0.409 REJECTIONS 6(5.9%) 9(8.9%) 0.593 TOTAL ACUTE REJECTIONS 17(16.8%) 24(23.7%) 0.502 REJECTION TYPE 0.486 ACR 7(6.9%) 12(11.9%) 0.486 ACR 7(6.9%) 12(11.9%) 0.486 ABMR 8(7.9%) 9(8.9%) 0.60 COMBINED 2(2%) 4(4%) 1.11	STEROID PULSE	15(14.9%)	17(16.8%)	0.230
RESPONSE TO STEROID PULSE 11(10.9%) 13(12.9%) 13(12.9%) 13(12.9%) 13(12.9%) 13(12.9%) 13(12.9%) 13(12.9%) 14(15.8%) 14(15.9%)	HOSPITAL STAY	l ,	, í	
PULSE 23.44+/-11.47 24.5+/-13.10 0.615 EARLY BIOPSY PROVEN REJECTIONS 11(10.9%) 16(15.8%) 0.409 REJECTIONS 6(5.9%) 9(8.9%) 0.593 TOTAL ACUTE REJECTIONS 17(16.8%) 24(23.7%) 0.502 REJECTION TYPE 4 0.486 ACR 7(6.9%) 12(11.9%) 0.486 ACR 7(6.9%) 9(8.9%) 0.486 COMBINED 2(2%) 4(4%) 4(4%) 4(4%) IV MP 5(5%) 4(4%	ATG SECONDARY	1(1%)	5(5%)	
DURATION HOSPITAL 23.44+/-11.47 24.5+/-13.10 0.615 EARLY BIOPSY PROVEN REJECTIONS 11(10.9%) 16(15.8%) 0.409 REJECTIONS 6(5.9%) 9(8.9%) 0.593 TOTAL ACUTE REJECTIONS 17(16.8%) 24(23.7%) 0.502 REJECTION TYPE 0.486 ACR 7(6.9%) 12(11.9%) 12(11.9%) ABMR 8(7.9%) 9(8.9%) 0.602 COMBINED 2(2%) 4(4%) 4(4%) IV MP 5(5%) 4(4%) 4(4%) IVMP,ATG 2(2%) 1(1%) 4(4%) ATG 4(4%) 8(7.9%) 4(4%) IVMP+PP+IVIG 1(1%) 2(2%) 1(1%) BORTEZOMIB 0 1(1%) 4(4%) BORTEZOMIB 0 1(1%) 4(4%) PP+IV IG 1(1%) 4(4%) 1(1%) PP+IV IG 1(1%) 4(4%) 1(1%) PP+IV IG 1(1%) 7(6.9%) 0.058 RECURRENCE 1	RESPONSE TO STEROID	11(10.9%)	13(12.9%)	
EARLY BIOPSY PROVEN 11(10.9%) 16(15.8%) 0.409 REJECTIONS 6(5.9%) 9(8.9%) 0.593 TOTAL ACUTE 17(16.8%) 24(23.7%) 0.502 REJECTIONS 0.486 0.486 ACR 7(6.9%) 12(11.9%) ABMR 8(7.9%) 9(8.9%) COMBINED 2(2%) 4(4%) TREATMENT RECEIVED 1V MP 5(5%) 4(4%) IVMP,ATG 2(2%) 1(1%) ATG IVMP+PHIVIG 1(1%) 0 0 PP+IVIG+ATG 1(1%) 2(2%) 0 BORTEZOMIB 0 1(1%) 0 ATG+IVIG 0 1(1%) 0 PP+IV IG 1(1%) 4(4%) 0 PP+IV IG 1(1%) 4(4%) 0 PP+IV IG+RITUXIMAB 0 1(1%) 0 0.058 RECURRENCE 1 1 1 0 0.058 RECURRENCE 1 1 1 0 <	PULSE			
REJECTIONS	DURATION HOSPITAL	23.44+/-11.47	24.5+/-13.10	0.615
LATE REJECTIONS	EARLY BIOPSY PROVEN	11(10.9%)	16(15.8%)	0.409
TOTAL ACUTE REJECTIONS 17(16.8%) 24(23.7%) 0.502 REJECTIONS 0.486 0.486 ACR 7(6.9%) 12(11.9%) ABMR 8(7.9%) 9(8.9%) COMBINED 2(2%) 4(4%) TREATMENT RECEIVED IVMP 5(5%) 4(4%) IVMP,ATG 2(2%) 1(1%) AC ATG 4(4%) 8(7.9%) AC IVMP+PP+IVIG 1(1%) 0 PO IVMP+PP+IVIG 1(1%) 2(2%) BO BORTEZOMIB 0 1(1%) 1(1%) ATG+IVIG 0 1(1%) PO PP+IV IG+RITUXIMAB 0 1(1%) 1(1%) NO TREATMENT GIVEN 2(2%) 1(1%) 1(1%) TREATMENT RESISTANT REJECTIONS 1(1%) 7(6.9%) 0.058 RECURRENCE I 1 1 IGAN 4 0 1 FSGS 2 0 0 DIABETIC 1 1 <th></th> <th></th> <th></th> <th></th>				
REJECTIONS 0.486 ACR 7(6.9%) 12(11.9%) ABMR 8(7.9%) 9(8.9%) COMBINED 2(2%) 4(4%) TREATMENT RECEIVED IV MP 5(5%) 4(4%) IVMP,ATG 2(2%) 1(1%) AG ATG 4(4%) 8(7.9%) IVMP+PP+IVIG IVMP+PP+IVIG 1(1%) 0 PP+IVIG+ATG 1(1%) 2(2%) BBORTEZOMIB 0 1(1%) AG+IVIG PP+IV IG 1(1%) 4(4%) PP+IV IG+IVIG 1(1%) AG+IVIG PP+IV IG+IVIXIMAB 0 1(1%) IVMP+PP+IV IG+IVIXIMAB 0 1(1%) IVMPP+IV IG+IVIXIMAB 0 1(1%) IVMPP+IV IG+IVIXIMAB 0 1(1%) IVMPPHPP+IV IG+IVIXIMAB 0 1(1%) IVMPPHPP+IV IG+IVIXIMAB 0 1(1%) IVMPPHPP+IVIGHPPHPPHPPHPPHPPHPPHPPHPPHPPHPPHPPHPPHPP	LATE REJECTIONS			0.593
REJECTION TYPE 0.486 ACR 7(6.9%) 12(11.9%) ABMR 8(7.9%) 9(8.9%) COMBINED 2(2%) 4(4%) TREATMENT RECEIVED IV MP 5(5%) 4(4%) IVMP,ATG 2(2%) 1(1%) ATG ATG 4(4%) 8(7.9%) ATG IVMP+PP+IVIG 1(1%) 0 PP+IVIG+ATG 1(1%) 2(2%) BORTEZOMIB 0 1(1%) ATG+IVIG 0 1(1%) PP+IVIGHATIC 0 1(1%) ATG+IVIG 0 1(1%) PP+IVIGHATIC 0 1(1%) 0 0 1(1%) PP+IVIGHATIC 0 0 1(1%) 0 0 1(1%) 0 0 1(1%)<		17(16.8%)	24(23.7%)	0.502
ACR 7(6.9%) 12(11.9%) ABMR 8(7.9%) 9(8.9%) COMBINED 2(2%) 4(4%) TREATMENT RECEIVED IV MP 5(5%) 4(4%) IVMP,ATG 2(2%) 1(1%) ATG 4(4%) 8(7.9%) IVMP+PP+IVIG 1(1%) 0 PP+IVIG+ATG 1(1%) 2(2%) BORTEZOMIB 0 1(1%) ATG-IVIG 0 1(1%) PP+IV IG 1(1%) 4(4%) PP+IV IG 1(1%) 4(4%) PP+IV IG 1(1%) 7(6.9%) NO TREATMENT GIVEN 2(2%) 1(1%) TREATMENT RESISTANT REJECTIONS RECURRENCE 1GAN 4 0 FSGS 2 0 DIABETIC NEPHROPATHY GRAFT NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING 9(8.9%) 11(10.9%) 0.814 GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	REJECTIONS			
ABMR 8(7.9%) 9(8.9%) COMBINED 2(2%) 4(4%) TREATMENT RECEIVED IV MP 5(5%) 4(4%) IVMP,ATG 2(2%) 1(1%) ATG 4(4%) 8(7.9%) IVMP+PP+IVIG 1(1%) 0 PP+IVIG+ATG 1(1%) 2(2%) BORTEZOMIB 0 1(1%) ATG+IVIG 0 1(1%) PP+IV IG 1(1%) 4(4%) PP+IV IG 1(1%) 4(4%) PP+IV IG 1(1%) 7(6.9%) NO TREATMENT GIVEN 2(2%) 1(1%) TREATMENT RESISTANT REJECTIONS RECURRENCE 1 IGAN 4 0 FSGS 2 0 DIABETIC NEPHROPATHY GRAFT NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING 9(8.9%) 11(10.9%) 0.814 GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	REJECTION TYPE			0.486
COMBINED 2(2%) 4(4%)	ACR	7(6.9%)	12(11.9%)	
TREATMENT RECEIVED IV MP 5(5%) 4(4%) IVMP,ATG 2(2%) 1(1%) ATG 4(4%) 8(7.9%) IVMP+PP+IVIG 1(1%) 0 0 0 0 0 0 0 0 0		8(7.9%)		
IV MP	COMBINED	2(2%)	4(4%)	
IVMP ,ATG	TREATMENT RECEIVED			
ATG 4(4%) 8(7.9%) IVMP+PP+IVIG 1(1%) 0 PP+IVIG+ATG 1(1%) 2(2%) BORTEZOMIB 0 1(1%) ATG+IVIG 0 1(1%) PP+IV IG 1(1%) 4(4%) PP+IV IG+RITUXIMAB 0 1(1%) NO TREATMENT GIVEN 2(2%) 1(1%) TREATMENT RESISTANT 1(1%) 7(6.9%) 0.058 RECURRENCE IGAN 4 0 FSGS 2 0 0 DIABETIC 1 1 NODAT NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING 9(8.9%) 11(10.9%) 0.814 GRAFT LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.		5(5%)	4(4%)	
IVMP+PP+IVIG		2(2%)	1(1%)	
PP+IVIG+ATG	ATG	4(4%)	8(7.9%)	
BORTEZOMIB	IVMP+PP+IVIG	1(1%)	0	
ATG+IVIG 0 I(1%) PP+IV IG 1(1%) 4(4%) PP+IV IG+RITUXIMAB 0 1(1%) NO TREATMENT GIVEN 2(2%) 1(1%) TREATMENT RESISTANT REJECTIONS 1(1%) 7(6.9%) 0.058 RECURRENCE IGAN 4 0 FSGS 2 0 DIABETIC NEPHROPATHY GRAFT 1 1 NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING 9(8.9%) 11(10.9%) 0.814 GRAFT LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	PP+IVIG+ATG	1(1%)	2(2%)	
PP+IV IG	BORTEZOMIB	0	1(1%)	
PP+IV IG+RITUXIMAB 0 1(1%) NO TREATMENT GIVEN 2(2%) 1(1%) TREATMENT RESISTANT REJECTIONS 1(1%) 7(6.9%) 0.058 RECURRENCE IGAN 4 0 FSGS 2 0 0 DIABETIC 1 1 1 NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING 9(8.9%) 11(10.9%) 0.814 GRAFT LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	ATG+IVIG	0	1(1%)	
NO TREATMENT GIVEN 2(2%) 1(1%) TREATMENT RESISTANT REJECTIONS 1(1%) 7(6.9%) 0.058 RECURRENCE IGAN 4 0 FSGS 2 0 0 DIABETIC NEPHROPATHY GRAFT 1 1 1 NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING GRAFT 9(8.9%) 11(10.9%) 0.814 LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	PP+IV IG	1(1%)	4(4%)	
TREATMENT RESISTANT REJECTIONS 1(1%) 7(6.9%) 0.058 RECURRENCE IGAN 4 0 FSGS 2 0 DIABETIC NEPHROPATHY GRAFT 1 1 NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING 9(8.9%) 11(10.9%) 0.814 GRAFT 15(14.9%) 22(21.8%) 0.205 GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	PP+IV IG+RITUXIMAB	0	1(1%)	
REJECTIONS BECURRENCE IGAN 4 0 FSGS 2 0 DIABETIC 1 1 NEPHROPATHY GRAFT 1 1 NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING GRAFT 9(8.9%) 11(10.9%) 0.814 LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	NO TREATMENT GIVEN	2(2%)	1(1%)	
RECURRENCE IGAN 4 0 FSGS 2 0 DIABETIC 1 1 NEPHROPATHY GRAFT 1 1 NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING 9(8.9%) 11(10.9%) 0.814 GRAFT LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	TREATMENT RESISTANT	1(1%)	7(6.9%)	0.058
IGAN 4 0 FSGS 2 0 DIABETIC NEPHROPATHY GRAFT 1 1 NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING GRAFT 9(8.9%) 11(10.9%) 0.814 LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	REJECTIONS			
TSGS 2 0 0	RECURRENCE			
DIABETIC NEPHROPATHY GRAFT 1 1 NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING GRAFT 9(8.9%) 11(10.9%) 0.814 LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	IGAN	1 '		
NEPHROPATHY GRAFT Section 19(18.8%) 0.394 NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING GRAFT 9(8.9%) 11(10.9%) 0.814 LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	FSGS	2	0	
NODAT 25(24.8%) 19(18.8%) 0.394 DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING GRAFT 9(8.9%) 11(10.9%) 0.814 LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205		1	1	
DEATH 14(13.9%) 12(11.9%) 0.834 CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING GRAFT 9(8.9%) 11(10.9%) 0.814 LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	NEPHROPATHY GRAFT			
CRAI 30(29.7%) 28(27.7%) 0.876 CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING GRAFT 9(8.9%) 11(10.9%) 0.814 LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	NODAT	25(24.8%)	19(18.8%)	0.394
CHRONIC REJECTION-TG 7(6.9%) 9(8.9%) 0.795 DEATH FUNCTIONING 9(8.9%) 11(10.9%) 0.814 GRAFT LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	DEATH	14(13.9%)	12(11.9%)	0.834
DEATH FUNCTIONING GRAFT 9(8.9%) 11(10.9%) 0.814 LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	CRAI	30(29.7%)		0.876
GRAFT 22(21.8%) LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205		7(6.9%)		0.795
LOST TO FOLLOW UP 15(14.9%) 22(21.8%) GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	DEATH FUNCTIONING	9(8.9%)	11(10.9%)	0.814
GRAFT SURVIVAL MEAN 58.87+/-37.49 50.95+/-38.85 0.205	GRAFT			
	LOST TO FOLLOW UP	15(14.9%)	22(21.8%)	
PATIENT SURVIVAL MEAN 59.36+/-37.68 53.30+/-39.61 0.260	GRAFT SURVIVAL MEAN	58.87+/-37.49	50.95+/-38.85	0.205
	PATIENT SURVIVAL MEAN	59.36+/-37.68	53.30+/-39.61	0.260








There were 11 biopsy proven early rejections in the SID group when compared to 16 in the SPD group (p=0.409). Number of late rejections were also more in the SPD group (9) compared to SID group (6)(p=0.593). Acute cellular rejections were more in the SPD group compared to SID group(6.9%,n=7, Vs 11.9%,n=12). Resistant rejections were more common in the SPD group compared to SID group (n=7 Vs n=1;p=0.058).5 patients in the SPD group required ATG for the treatment of Steroid resistant rejection whereas only one pt required it in SID group.

The incidence of PTDM was more in the SID group (24.8% Vs 18.8%)but was not statistically significant(p=0.354). Biopsy proven recurrence of basic diseases was more common in SID group with recurrence noted in 7 patients out of which 4 were IgA Nephropthy,2 were FSGS,1 was Diabetic Nephropathy. Only one case of recurrence was noted in spousal group diabetic nephropathy


5(14.9%) (3%) 5(14.9%)	10(9.9%) 4(4%) 14(13.9%)	0.393 0.710 >0.0
(3%)	4(4%)	0.710
5(14.9%)	14(13.9%)	>0.0
` ′		
		5
0(19.8%)	20(19.8%)	
3(12.9%)	20(19.8%)	
(4%)	4(4%)	
(1%)	2(2%)	
(1%)	1(1%)	
(1%)	0	
	2 (2%)	
6(15.8%)	7(6.9%)	
(6.9%)	6(5.9%)	0.584
		0.549
(1%)	2(2%)	
(2%)	4(4%)	
(3%)	1(1%)	
(1%)	0	
1	1(1%)	
		0.591
MULTIPLE	1 HEPATOCELLAR	
MYELOMA	CARCINOMA	
	3(12.9%) (4%) (1%) (1%) (1%) (6(15.8%) (6.9%) (1%) (2%) (3%) (1%) MULTIPLE	3(12.9%) 20(19.8%) (4%) 4(4%) (1%) 2(2%) (1%) 1(1%) (1%) 0 2 (2%) (6(15.8%) 7(6.9%) (6.9%) 6(5.9%) (1%) 2(2%) (2%) 4(4%) (3%) 1(1%) (1%) 0 1(1%) MULTIPLE 1 HEPATOCELLAR


Bacterial ,fungal and viral infections were similar between two groups except CMV disease which is more common in SID group compared to SPD group(14.9%,n=15 Vs 9.9%,n=10;p=0.393). Incidence of post-transplant Malignancies was similar ,one patient in SID group developed Multiple Myeloma and one patient in SPD group developed Hepatocellar carcinoma.


Kaplan meier curves showing patient and graft survival rates of Sibling donor (SID) and Spousal donor (SPD) transplant recipients



Graft survival rate was less in SPD group compared to SID group in Kaplan Meier survival curve but there was no significant difference in patient survival. Five year graft survival rates were 98% and 92% respectively.







Pt survival rates	1yr	3yr	5yr	7yr	10yr
Sibling Donor	95%	93%	90%	83%	74%
Spousal Donor	93%	89%	89%	86%	82%

Graft survival rates	1yr	3yr	5yr	7yr	10yr
Sibling Donor	100%	98%	98%	98%	86%
Spousal donor	99%	94%	92%	92%	92%

Using Spearman's correlation coefficient it was found that graft survival in our study was significantly correlated to HLA matching hospital stay duration and CRAI.

DEATHS	6	6
CAUSE OF DEATH		
LRTI SEPSIS SEPTIC SHOCK	5(5%)	5(5%)
PYELONEPHRITIS SEPSIS SEPTIC SHOCK	1(1%)	0
DENGUE SHOCK SYNDROME		1(1%)

Six deaths occurred in either group,out of which 5 were due to Lower respiratory tract infection severe sepsis and shock.

Graft loss progressing to ESRD was observed in 3 patients in the SID group and 5 patients in the SPD group.

GRAFT LOSS		
GRAFT LUSS		
GRAFT LOSS-ESRD	3(3%)	5(5%)
GRAFT LOSS CAUSE		
BK VIRUS NEPHROPATHY	1	
VIRAL CYTOPATHIC CHANGES-CRAI	1	
RECURRENT FSGS	1	
CRAI -LRTI		1
HYDRONEPHROSIS		1
RECURRENT HUS-REJECTION		1
CRAI-UROSEPSIS		1
PYONEPHROSIS-NEPHRECTOMY		1

DISCUSSION

Kidney transplants have been done with biologically unrelated donors in different parts of the world. This was unregulated in many parts of the world including India resulting in organ trade and clandestine transplantation surgeries. The situation changed in India after the Transplantation of Human Organs Act,1994(4) was passed. This act defines near relative as spouse,son,daughter,father,mother,brother or sister. Recently the Transplantation of Human Organs and Tissues rules, 2014 dictates the guidelines for Living and cadaveric Kidney donation. Living unrelated donor renal transplantation is not routinely performed in our centre but spousal renal transplantation is performed in our centre. Spouses who have completed at least 3 years of marriage are accepted as donors. Donation is also accepted if consummation of marriage has occurred. Similar policy has been followed in AIIMS, New Delhi (6,7). In united kingdom uses ULTRA for assessment of issues related to genetically unrelated donor. (8)

The number of sibling donors decreased over the years(6). There is a steady increase in the number of spousal donors in the recent years in different centres in India (9) and all over the world(10). Spousal donation embodies emotional attachment between spouses and ensures better compliance with immunosuppression and follow up. Family psychodynamics ,sexual relationship and relationship with children improves with spousal donation(11–13). Spouse as donor comparable to the parental donor and better than the cadaveric donor advocated by Terasaki 1995(1). It also ensures quicker decision, easy coordination(12) when compared to sibling donors.

The immunological matching between donor and recipient using HLA compares with that of the Matter etal Fuller etal Humar etal(14–16). The immunosuppressive protocols were almost similar between the two groups in terms of Induction and Maintenance immunosuppression. Most patients received Cyclosporine as immunosuppression before 2009 which changed to Tacrolimus during 2009-2010 period and completely replaced by Tacrolimus in the years after. This was taken care by selecting the recipients from the same year so that there was no significant difference between the two groups.

In previous studies of Matter etal(14) there was significant donor age difference of the between genetically unrelated donors..Noppakun etal study(17) concluded that the Donor's age influences the transplant outcomes.Our present study has age matched groups eliminating the bias

The graft survival rates and the patient survival rates were similar between the two groups. (89% vs 90%) similar to Tang etal, Gjertson et al, Yoon et al (18–20). Mukharjee et al Kute et al (21,22) reported similar graft survival rates but statistically significant difference in patient survival between spousal and related donor groups. Biopsy proven early rejections were more common in the spousal donor

group(15.8%) compared to the sibling group (10.9%) but not statistically significantsimilar to Tang et al Mukharjee et al.(18.21)...This contrasts to the Matter YE etal. Fuller etal, and Matas A J etal(14,15) where there were statistically significant high incidence of acute rejections in spousal donor group(23).

LIMITATIONS

The main limitation of the present study is 15% -20% of the recipients lost to follow up and the sample size is less(n=101) in each group but matched to the age and sex of donor and year of transplant to ensure comparability between the groups.ABO incompatible transplants were not included in the present study.

CONCLUSION

Spouse as a kidney donor is an ethically viable option in this era where there are unwilling siblings and unfit parents.

REFERENCES

- Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med. 1995 Aug 10;333(6):333–6.
- Takemoto S, Port FK, Claas FHJ, Duquesnoy RJ. HLA matching for kidney transplantation. Hum Immunol. 2004 Dec;65(12):1489–505
- Chugh KS, Jha V. Commerce in transplantation in Third World countries. Kidney Int. 1996 May: 49(5): 1181-6.
- Nundy S. Origin and genesis of the Transplantation of Human Organs Act, 1994, of
- India. Int Dig Health Legis. 1996;47(1):88–90.

 Lim WH, McDonald SP, Coates PT, Chapman JR, Russ GR, Wong G, Maternal compared with paternal donor kidneys are associated with poorer graft outcomes after kidney transplantation. Kidney Int. 2016 Mar;89(3):659–65.

 Bhowmik D, Dash SC, Tiwari SC, Agarwal SK, Gupta S, Guleria S, et al. Spousal renal
- donor transplants in India. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 1999 Aug;14(8):2052–3.

 Dash SC, Bhowmik D. The wife as kidney donor: current Indian scenario. Kidney Int.
- 2001 Feb;59(2):801.
- Mathieson PW, Jolliffe D, Jolliffe R, Dudley CR, Hamilton K, Lear PA. The spouse as a kidney donor: ethically sound? Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 1999 Jan;14(1):46–8.
- Sakhuja V, Kumar V. Spouses as kidney donors in India: Trends and outcomes. Indian J Nephrol. 2014 Jan; 24(1):1–2. Chung BH, Jung MH, Bae SH, Kang SH, Hwang HS, Hyoung BJ, et al. Changing Donor
- Source Pattern for Kidney Transplantation over 40 Years: A Single-Center Experience. Korean Jintern Med. 2010 Sep;25(3):288–93.
 Watanabe T, Hiraga S. Influence on family psychodynamics on spousal kidney
- transplantation. Transplant Proc. 2002 Jun;34(4):1145–7.
 Binet I, Bock AH, Vogelbach P, Gasser T, Kiss A, Brunner F, et al. Outcome in emotionally related living kidney donor transplantation. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 1997 Sep;12(9):1940-8.
- Spital A. Do U.S. transplant centers encourage emotionally related kidney donation? 13. Transplantation. 1996 Feb 15;61(3):374–7.
- Matter YE, Nagib AM, Lotty OE, Alsayed AM, Donia AF, Refaie AF, et al. Impact of Donor Source on the Outcome of Live Donor Kidney Transplantation: A Single Center
- Experience. Nephro-Urol Mon. 2016 May;8(3):e34770.
 Fuller TF, Feng S, Brennan TV, Tomlanovich S, Bostrom A, Freise CE. Increased rejection in living unrelated versus living related kidney transplants does not affect short-term function and survival. Transplantation. 2004 Oct 15;78(7):1030–5.
- Living Unrelated Donors in Kidney Transplants: Better Long-Term Results Than With Non-Hla-Identical Living Related Donors? [Internet]. PubMed Journals. [cited 2017 Feb 24]. Available from: https://ncbi.nlm.nih.gov/labs/articles/10830235/ Noppakun K, Cosio FG, Dean PG, Taler SJ, Wauters R, Grande JP. Living donor age and
- kidney transplant outcomes. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2011 Jun;11(6):1279–86.
 Tang S, Lui SL, Lo CY, Lo WK, Cheng IKP, Lai KN, et al. Spousal renal donor
- transplantation in Chinese subjects: a 10 year experience from a single centre. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2004
- Gjertson DW, Cecka JM. Living unrelated donor kidney transplantation. Kidney Int. 2000 Aug;58(2):491-9.
- Yoon HE, Song JC, Hyoung BJ, Hwang HS, Lee SY, Jeon YJ, et al. Comparison of longterm outcomes between spousal transplants and other living unrelated donor transplants: single-center experience. Nephron Clin Pract. 2009;113(4):c241-249.
- Mukherjee A, Kekre NS, Gopalakrishnan G. The spouse as a donor in renal transplants. Saudi J Kidney Dis Transplant Off Publ Saudi Cent Organ Transplant Saudi Arab. 2006
- Kute VB, Shah PR, Vanikar AV, Gumber MR, Goplani KR, Patel HV, et al. Long-term outcomes of renal transplants from spousal and living-related and other living-unrelated donors: a single center experience. J Assoc Physicians India. 2012 Jul;60:24-7
- Matas AJ. Pavne WD, Sutherland DER, Humar A, Gruessner RWG, Kandaswamy R, et al. 2,500 Living Donor Kidney Transplants: A Single-Center Experience. Ann Surg. 2001 Aug;234(2):149-64.